COVID-19: Guidance for infection prevention and control in nuclear medicine

With thanks to Dr. Alp Notghi, Dr. Manish Pandit and Joe O’Brien (Sandwell and West Birmingham Hospitals) and Dr. Sobhan Vinjamuri (Royal Liverpool University Hospital)

Updated 11th January 2021

Bearing in mind the rapid speed with which the situation is changing, this guidance should be read in conjunction with current government and your local Trust advice. Though there will be local differences and the situation may change from week to week it is our understanding that urgent and cancer based patient management should continue if possible.

Social distancing and self-isolation are key measures now being enforced by the government to slow down the spread of the Coronavirus. In non-urgent patients this will be enhanced by the use of COVID-19 testing of both staff and patients. This is in particular for vulnerable groups where shielding is recommended but this should not be a bar to receiving appropriate nuclear medicine scans and treatment. In keeping with this and the fact that higher proportion of those attending clinics and hospital investigations often have co-existing risk factors, we advise that non-urgent out-patient appointments are reviewed by the Lead clinician to decide which studies can be postponed until such time that Her Majesty’s Government relaxes these measures. In this way, the pressure being placed on the NHS by critically ill patients can be eased, and the risk of COVID-19 infection to patients, their relatives and to NHS staff can be reduced. Nuclear medicine is a specialised procedure and staff cannot be easily replaced in the event of shortage. This also helps ease the pressure in the possible reduced workforce in view of the effect restrictions can have on staffing of the departments.

Contents

Closing departments
Re-purposing or Sharing Radiopharmacy Facilities
Radiopharmacy Contingency Plans
Postponing appointments
Delivery of radiopharmaceuticals
Table 1: Guidance for rebooking Nuclear Medicine tests
Booked appointments
Symptomatic patients
Expensive tests
Patient areas
Patient hand hygiene
Staff Hand hygiene
PPE
Equipment
Legal Considerations
Some hospitals are coming under severe stress due to the number of COVID-19 patients admitted. Therefore, some departments of nuclear medicine may be asked to close to concentrate resources of the hospital to deal with COVID-19 patients. This may result in staff being re-assigned to new roles during this crisis or staff may be furloughed. The decision to close a department can only be taken by senior management of the Hospital/Trust. As it is vital that urgent non-COVID-19 patients and those with cancer continue to receive the care they need any closure of a department must also include instructions as to where patients will be scanned and treated. A mechanism will need to be set up to ensure patient’s referrals are forwarded promptly and results returned in a timely manner. It is vital that patients are kept fully aware of the situation and that their enquiries can be fully dealt with. It may be possible in some areas of the country to use nuclear medicine facilities in private hospitals to ensure a service can continue.

Some departments may be asked to reduce activity to release staff to other duties. This may mean that only a limited number of tests can be done. Please see Table 1 for guidance.

If your department is no longer able to offer nuclear medicine studies some administrative and clinical staff should remain on duty even if working from home. Any patient who needs an urgent scan or treatment your department cannot offer should be asked if they are willing to travel to a department that can offer that scan or treatment.

If your department remains open and working please consider referrals from those hospitals that have had to reduce or stop activity so that patient scans and treatments are not delayed.

**Re-purposing or Sharing Radiopharmacy Facilities**

The removal in non-urgent Nuclear Medicine work will result in a reduction of workload in the Radiopharmacy. Alongside this is a potential increase in other aseptic work in the hospital as pharmacy departments are called on to supply increased number of products to critical care, for example. The use of Radiopharmacies for other activities, such as provision of a CIVAS service or to make products such as hand gel for example, may be required. For the larger units, it may be possible to convert part of the facility for this purpose; smaller units may have to use the same areas. For all units, separation of the activities by time should be considered in order to minimise risk of radioactive contamination. If this is being planned, there are a number of factors to be considered, such as licensing status, liaison with the MHRA, training of staff, risk assessments and Local Rules. The UK Radiopharmacy Group will soon have advice on its website on sharing facilities.

**Radiopharmacy Contingency Plans**
Another consideration for the Radiopharmacy is contingency planning in the event there are insufficient staff to run the service, or to rationalise the use of PPE and cleaning materials. In this case, close liaison with neighbouring Radiopharmacies is important. For example, Radiopharmacy staff in other units could be trained to support a ‘supply hub’ whereby, should there be staffing shortages at any of the units, the workload could be consolidated in one place. The choice of supply hub should take into account location, experience of providing a centralised service and the existence of procedures and systems already in place to support this. Early training should be undertaken to support this proposal and availability of trained drivers must be taken into account. Any contingencies should be risk assessed, and the MHRA should be informed as well as the local HR department.

**Postponing appointments:**

Nuclear medicine departments often have administration staff dedicated to their services. Many are likely to have hundreds of scans booked and requested awaiting booking. It is important that all referrals are reviewed for clinical urgency by the clinical lead or their appointed deputy who would normally be a Consultant. All new referrals should be reviewed in a similar way. It is vital the Consultant reviewing each request has sufficient information to not only determine how urgent the scan or treatment is but other co-morbidities and the patient’s vaccination status. For hospitals using paper medical records these may need to be reviewed. To act on these quickly, administration staff from other modalities may have to assist, hence nuclear medicine should co-ordinate with other imaging modalities when considering the approach to postponing appointments as help may be needed, especially as some may begin to isolate.

A suggested pathway for the process of cancelling appointments can be found in Appendix 1. The most important consideration is the assessment of the risk of postponement. It is important that those patients which urgently need their Nuclear Medicine tests are still able to have them. The prioritisation of patient appointments must therefore be carefully considered. Those for chronic conditions have lower priority compared to acute/severe conditions. A traffic light system is proposed in table 1 below to assist with the decision making process using the following guidelines:

- Tests in green category can be cancelled (i.e. postponed) and possibly held in a queue until the situation is clear and/or rebooked as and when needed.
- Amber appointments must be discussed with a clinician beforehand if considering cancelling/rebooking. Note: patients may have had withdrawal of some of their existing drug treatment, and this should be considered when making the decision on whether to postpone of not (for example, thyroid and parathyroid scans when using I$^{123}$)
- Red appointments should not be cancelled as they are deemed essential, unless under extreme circumstances.

It is recommended that the examination not be re-booked until further advice has been received; rather it should be kept on file and once the department is in a position to reschedule the patient’s appointment, then they should be contacted at that point. We understand that patients may have been waiting for these tests for a long time and for some the test has significant impact on their life; if the patient wants to appeal the decision, then they should contact their referring doctor, who should then have a discussion with the Nuclear Medicine Clinician regarding the urgency of the request, if appropriate.
**Delivery of radiopharmaceuticals**

Nuclear Medicine Europe issued a statement on 25th March 2020. At present there has been no problem with production facilities in both Europe and those centres outside Europe we depend on. However, there may be issues with delivery of these radiopharmaceuticals within Europe partly related by the paucity of flights especially where radiopharmaceuticals are carried as hold luggage in passenger airliners. Also there may be future issues with road transport both across borders and within borders. Please be aware of these possible issues.

**Table 1: Guidance for rebooking Nuclear Medicine tests**

<table>
<thead>
<tr>
<th>Red</th>
<th>Amber</th>
<th>Green</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not cancel or rebook unless patient at risk</td>
<td>Discuss with clinician if there is a need to cancel/rebook. New referrals to be discussed</td>
<td>Rebook without need for discussion with a clinician</td>
</tr>
<tr>
<td>Book all new referrals</td>
<td></td>
<td>Do not book new appointments</td>
</tr>
<tr>
<td>F-18 FDG new cancer</td>
<td>F-18 FDG follow up non lymphoma</td>
<td>2 phase bones and non-oncology Whole body bone</td>
</tr>
<tr>
<td>F-18 FDG in interim and post therapy assessment of treatment of lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F-18 FDG in suspected recurrent cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F-18 FDG sepsis including looking for active lung disease in COVID-19</td>
<td>Ga-68 DOTATATE follow up</td>
<td>Amyloid DPD</td>
</tr>
<tr>
<td>F-18/Ga-68/Tc-99m PSMA/F-18 Choline new cancer</td>
<td>Ga PSMA/F-18 Choline follow up</td>
<td></td>
</tr>
<tr>
<td>Ga-68 DOTATATE (staging / therapy decision)</td>
<td>Ga-68 PSMA follow up</td>
<td>C13 UBT</td>
</tr>
<tr>
<td>GFR</td>
<td>Lung VQ</td>
<td>Colonic Transit</td>
</tr>
<tr>
<td>Gi bleed</td>
<td>Mag3</td>
<td>CSF studies</td>
</tr>
<tr>
<td>In-111 Pentetreotide (Octreoscan)</td>
<td>MIBG pheochromocytoma</td>
<td>Dacroscintigraphy</td>
</tr>
<tr>
<td>Lu-177 DOTATATE</td>
<td>MPS routine (SOB)</td>
<td>DMSA</td>
</tr>
<tr>
<td>Lung perfusion</td>
<td>MUGA - cardiac</td>
<td>Gastric Emptying</td>
</tr>
<tr>
<td>Meckels</td>
<td>Parathyroid (bear in mind cessation of drug therapy in lead up)</td>
<td>HIDA</td>
</tr>
<tr>
<td>MPS acute chest pain</td>
<td>Platelet survival</td>
<td>I-123 Ioflupane (DaTSCAN)</td>
</tr>
<tr>
<td>MUGA Oncology</td>
<td>Thyroid Tc-99m/ I-123 (paeds)</td>
<td>Lymphoscintigraphy</td>
</tr>
<tr>
<td>Oncology Bones</td>
<td>White cell (also consider FDG)</td>
<td>MIBG heart</td>
</tr>
<tr>
<td>Radium-223</td>
<td>Benign Thyroid therapy</td>
<td>Morphine HIDA</td>
</tr>
<tr>
<td>SLN</td>
<td>Platelets</td>
<td></td>
</tr>
<tr>
<td>99mTc-EDDA/HYNIC-TOC (Tektrotyd)</td>
<td></td>
<td>Proctoscintigraphy</td>
</tr>
<tr>
<td>Y90-SIRT</td>
<td></td>
<td>Red Cell Mass</td>
</tr>
<tr>
<td>I-131 therapy malignant disease</td>
<td></td>
<td>Salivary</td>
</tr>
</tbody>
</table>
Se-75 / Tauroselcholic acid (SeHCAT)
Small bowel transit
Thyroid Tc-99m/ I-123 (adults)
TI-201 hibernation

**Booked appointments:**
Even for those appointments which are deemed to be urgently required, there is an increased risk of DNAs as patients may develop symptoms themselves, or may be self-isolating because of their age, or because someone else in their household has developed symptoms. It is advised that departments contact patients by phone the day before to check their symptoms and to ask if they are still planning to attend. Symptoms which could be associated with the virus are high temperature, cough, and more recently reported, a loss of taste or sense of smell.

**Symptomatic patients:**
Any patient showing symptoms of the virus (fever, or persistent dry cough) should be told not to attend, and sent home if they do present at the department, and the procedure rebooked, even if they are attending for a high priority (red) procedure, or even if they have been injected with the radiopharmaceutical.

**Expensive tests:**
Where possible delay these tests until this crisis is over if expensive radiopharmaceuticals are bought in, appointments should be reviewed before booking to avoid expensive DNAs, and it should be confirmed that the product can still be supplied as there may be some disruption to this.

**Patient preparation:**
It is important to follow your hospital/Trust’s policy concerning pre-appointment testing but we would recommend that all patients over 12 should have a negative COVID-19 PCR performed within 96 hours of their appointment. If this is not possible the reason for this should be recorded. At present vaccination is not seen as a reason not to have a pre-appointment COVID-19 test. 10 days isolation is only recommended for those coming for radionuclide therapies or who may need to be in-patients for their scan or treatment. You should be guided by your hospital/Trust policy

**Patient areas:**
Look at patient wait areas try to ensure these do not get crowded. Ask patients coming to cold wait not to arrive more than 5 minutes before their appointment. Ideally the patient should attend by themselves, but if they need to have another person with them – for example, a carer, interpreter or driver, a maximum of one adult can come with them. No children should accompany them. After injections if possible the patients should be asked to keep distance and if possible to wait outside (including in the cars) and arrive back 5 minutes before the given imaging time. Keep the hot wait for those who cannot physically leave the department. All patient wait areas should be wiped down with appropriate sanitiser at least every 2 hours.

**Patient hand hygiene, masks etc:**
All patients should wear a mask that covers their nose and mouth unless they are exempt. On entry to the hospital they should be questioned concerning COVID symptoms and be temperature checked. If this is not done this should be done when they report to nuclear medicine. Patients should be asked to clean their hands when they arrive and before they come in to the scanning rooms, preferably by handwashing, although alcohol gel can also be used. Signage is helpful with this.

**Vaccination:**
Present data shows that the authorised COVID-19 vaccinations provide protection reducing the risk of contracting COVID-19 and if this occurs reducing the risk of hospitalisation and death. At present vaccination should be viewed as the most effective risk reduction strategy and as such all nuclear medicine staff unless contra-indicated should have the COVID-19 vaccination. What is not clear is whether vaccination reduces transmission of the virus so at present staff who are vaccinated should continue to use appropriate testing, PPE and infection control. Patients who have been vaccinated should be considered to be at a lower risk of contracting COVID-19 but as that risk has not been reduced to zero should also continue to comply with all the requirements for safe practice.

**Staff Hand hygiene:**
Staff should clean their hands at regular intervals during the day for 20 seconds each time using soap and running water. Ideally gloves should be worn when handling patients, for example, when helping them on and off the bed. These must be changed between each patient contact. Staff should also wash/sanitise hands before / after every patient, even if wearing gloves. Hand moisturisers must be used to ensure the skin does not become affected by repeated washing. Avoid touching face with hands.

**PPE:**
Unless exempt and with specific approval from the departmental manager and clinical lead. All staff should wear a face mask which covers the mouth and nose. These should not be worn for more than 4 hours before changing. Triple layer paper surgical masks are the most appropriate. Please follow your local policy for which PPE to wear. Example guidance on what PPE to wear in nuclear medicine and when to wear it is given in Appendix 4 and supplies may have to be centralised. PPE should be kept in all injection rooms (i.e. more than one location) in case of inaccessibility due to radioactive contamination. Different PPE may need to be worn outside of Nuclear Medicine, for example, on the ward. Follow Local Trust Policies for this. Regular stock takes should be made to ensure there will be no shortage.

**Equipment:**
- If possible, one camera should be set aside for non-symptomatic patients only (out or inpatients) with a different cameras being reserved for symptomatic / unconfirmed / confirmed patients whenever possible.
- *Cleaning & Decontamination:* camera rooms should be cleaned down after each patient and surfaces such as couch, chairs wiped down with a sanicloth or equivalent. After a symptomatic / confirmed Covid-19 patient and sufficient time should be allowed between patients to allow for air re-circulations. Please refer to your room specification (often held by hospital estates department) as to how much time is needed for room re-circulations which
is room/air-con specific. Air conditioning with re-circulation should only be used with a high efficiency particulate (HEPA) filter in situ. The filter should be changed frequently.

- Symptomatic / unconfirmed / confirmed Covid-19 patients should be brought immediately into the camera room and not left waiting anywhere else.
- The ideal time to perform scans of infectious patients is in the afternoon to minimise cross contamination after use. However, in the afternoon, you will end up injecting more particles of MMA (unless the MAA is prepared at lunch time). Also, the Kr generator will be weaker. So morning appointments are preferred.

**Legal Considerations:**

*Environmental Permitting Regulations / Radioactive Substances Act (for Northern Ireland):*

If applicable, departments should review their procedure for timing of radioactive waste collection. A slightly earlier prompt to start the consignment procedure is advised in case of disruption to the courier service. For example, those with a 90day permit, may want to consider a prompt to begin preparing for consignment at 65 rather than 70 days, assuming the contents can be consigned at this date from a transport regulations perspective.

**IRMER:**

Departments should keep to their usual equipment QC procedures and schedules. But it is advised to consider contingency planning for lack of immediate MPE advice, such as provision of MPE advice remotely if possible. Effective communication is important, particularly in the event any of the results are borderline and the MPE is not available for advice.

Departments should perform vetting procedures as usual, but prepare for situations where the practitioner, or those delegated to authorise tests, are not available in the department due to Covid-19.

**Precautions for Lung Imaging:**

**VQ Scan for known Covid-19 patients**

- The decision on whether to proceed with the VQ should be discussed with the referrer before booking.
- Most in-patient referrals are for VQ scans and these could include suspected or confirmed in-patient Covid-19 positive patients. Please consider all in-patient VQs with uncertain COVID-19 status as potentially positive and wear appropriate PPE.
- The use of a perfusion only scan is unlikely to be of any benefit if Covid-19 infection is suspected as the Coronavirus response PROBABLY alters MAA distribution. In other words, it is unlikely for a perfusion only study to be normal.
- The majority of referrals to VQ in most departments are the pregnant patients and the perfusion only scan is often normal, with no requirement to proceed to more “intimate” contact through use of masks. This is only possible in department with hot reporting (as the study is finished) to determine if patient needs ventilation in some cases.
- Pregnant patients are in a higher risk category and should be in the department for as short a time as possible.
- If using Krypton, proceed with a dual energy Tc-MAA/Kr-gas VQ to complete the test quickly.
Only perform ventilation at the same time if you have Krypton-81m available. Other ventilation agents may not be suitable due to the time required to be with the patient, and the unsatisfactory distribution due to likely patient non-compliance. If Technegas or aerosol is used follow the manufacturer’s guidance [https://www.cyclomedica.com/wp-content/uploads/sites/20/2020/03/Technegas-and-COVID-19-letter.pdf](https://www.cyclomedica.com/wp-content/uploads/sites/20/2020/03/Technegas-and-COVID-19-letter.pdf).

For non-pregnant, and non-hypertensive patients, consider increasing the DRL from 200MBq to 300MBq to bring about rapid SPECT imaging (5mins cp 12 mins). It would also reduce the time the patient and accompanying ward staff are in the department. Note: all referrals must be vetted by the ARSAC licence holder in this case as it involves an increased DRL.

Patients with pulmonary hypertension should only receive 200MBq and always injected soon after preparation of MAA to reduce the number of particles (this usually means in the morning).

If more than one referral is made, these should be booked and performed consecutively, allowing for sufficient room re-circulations. National guidance states “A minimum of 20 minutes i.e. 2 air changes, in hospital settings where the majority of these procedures occur is considered pragmatic”.

For all other VQ scans (i.e. those non-symptomatic for Covid-19), whether in-patient or outpatient, the operator should wear a surgical mask, gloves and gown.

Use disposable tourniquets and any disposable waste from the procedure should be bagged in suitable waste bags as recommended by the local hospital.

When performing a VQ scan on suspected or confirmed Covid-19 patients, the NM operator of choice would be those with no other medical conditions.


Though ventilation scans are not considered to be aerosol generating procedures by NHS England given that the patient is likely to be having some degree of respiratory distress and possibly a cough. Each patient should be risk assessed before considering a lung ventilations scan. If it is decided a lung ventilation scan is warranted; then staff safety must also be considered. We recommend the operators in close contact with the patient including injector and patient’s mask fitter should wear appropriate PPE as determined by a risk assessment of each patient’s condition and Trust/Hospital’s PPE policy. Such PPE is considered essential if the operator must remain in close contact for example holding the ventilation mask onto the patient if they are unable to do this themselves. These procedures should be used will ALL ventilation agents as the risk is related to the patient not the ventilation technique used.

A proposed plan for VQs can be found in appendix 5.

**Special Advice for booking Sentinel Lymph Node (SLN)**

Nuclear Medicine Departments are advised to liaise frequently with the SLN services they support as these procedures are likely to be altered due to their own internal priority systems.

**Reporting Nuclear Medicine and MDTs:**
- Once scans are being / have been performed, remote reporting options could be explored in conjunction with radiology/PACS/ IT teams.
- Participation in MDTs can be limited in line with national guidance, please ensure ability to dial in remotely and rotation of staff attending MDTs

**PET-CT:**
- We expect that demand for PET-CT may reduce a little with less “follow up” scans but generally there will still be a significant work load. If you have separate uptake rooms not being used for PET, consider using these areas for “at risk” patients from the rest of imaging.
- Be prepared to use any spare CT capacity on the machine for acute chest CTs as throughout put on CT scanners may be reduced by need to clean room between patients
- We advise reviewing the CT component of PET-CT on lung windows to check that patients do not have incidental signs of viral infection before they leave the scanner. If there are signs the scanner needs to be cleaned prior to the next patient in case the patient has Covid-19. Please see information on the BSTI website for CT appearances that are seen in Covid-19: https://www.bsti.org.uk/covid-19-resources/.

**SPECT-CT:**
- We advise reviewing the CT component of PET-CT on lung windows to check that patients do not have incidental signs of viral infection before they leave the scanner. If there are signs the scanner needs to be cleaned prior to the next patient in case the patient has Covid-19. Please see information on the BSTI website for CT appearances that are seen in Covid-19: https://www.bsti.org.uk/covid-19-resources/.

**Therapeutic Nuclear Medicine:**
- Each patient needs to be assessed on an individual basis.
- Radioiodine therapy appointments for benign Hyperthyroidism may need to be delayed but considering the potential immunosuppression caused by carbimazole and PTU in some patients a service should still be offered However, consideration should be given to giving the treatment to those patients who are unable to tolerate anti-thyroid medications, or those who have other severe comorbid issues, whereby a delay in treatment would cause more harm than good.
- Administration of radioiodine ablation therapy to Thyroid cancer patients needs careful consideration. However, in general patient’s treatment should not be delayed unless the patient has specific additional risk factors. Please follow the RCR Thyroid Cancer guidance for actions to be taken for low, medium and high risk patients in terms of delay of treatment and measures to be taken should the decision be made to go ahead with treatment.
- Lutathera for patients with low and medium grade Neuroendocrine tumours will need to be reviewed in light of local risk assessments/guidelines. However, since some of these patients could be considered as at risk due to possible marrow depletion post procedure, it may be safer to defer treatment for a few months. Each patient should be reviewed in their own clinical and local contexts. It is generally expected that the majority of Lutathera treatments should proceed without delay.
• Radium-223 dichloride can be administered as an outpatient procedure, provided the patients do not have comorbidities that would put them at high risk due to low immunity. Please review each patient in their own clinical and local contexts. Please note both NICE and the RCR recommend Radium-223 instead of immunosuppressive chemotherapy in patients with castrate resistant bone dominant metastases. These patients will be funded in England through the “blueteq” system
• It may be as data comes available patients who have received the first dose of the COVID vaccine may be considered to be low risk.
Appendix 1: Proposed Pathway for Rationalising Imaging Outpatients

Immediate actions:
- General message to be sent out to referrers
- Cancellation letter to be drafted and added to automatic systems
- Script for cancellation to be agreed to avoid panic

‘Green’ patient appointments to be removed (low risk)
Referrers instructed to contact to appeal if disagree
All ‘red’ patient appointments to be booked as normal

Remaining referrals reviewed by Nuclear Medicine clinician
Consider when booking - cancer, chest pain, trauma

Message re postponement e-mailed to referrers.
Grouped if possible
Individual discussion at discretion of Imaging Clinician

Patients asked to contact referrer if they believe their scan is urgent
Referrers to be asked to e-mail Nuclear Medicine Clinician if they disagree with postponement; they will discuss and rebook as necessary

Patient to be added back to waiting list; await further instruction on when to resume booking
Appendix 2: Suggested template for departmental signage

---

HM Government

NHS

**CORONAVIRUS**

Have you been to an affected place in the last 14 days

or

had contact with somebody with Coronavirus,

and

do you have any of these symptoms?

- Cough
- Fever
- Shortness of breath

If yes, to protect yourself and others please go home and phone your GP or NHS 24 (111) for advice.

Please do not enter this building

Find out more at gov.uk/coronavirus
### Appendix 3: Coronavirus symptoms compared with flu and the common cold

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Coronavirus</th>
<th>Cold</th>
<th>Flu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>Common</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Sometimes</td>
<td>Sometimes</td>
<td>Common</td>
</tr>
<tr>
<td>Cough</td>
<td>Common* (usually dry)</td>
<td>Mild</td>
<td>Common* (usually dry)</td>
</tr>
<tr>
<td>Sneezing</td>
<td>No</td>
<td>Common</td>
<td>No</td>
</tr>
<tr>
<td>Aches and pains</td>
<td>Sometimes</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Runny or stuffy nose</td>
<td>Rare</td>
<td>Common</td>
<td>Sometimes</td>
</tr>
<tr>
<td>Sore throat</td>
<td>Sometimes</td>
<td>Common</td>
<td>Sometimes</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Rare</td>
<td>No</td>
<td>Sometimes for children</td>
</tr>
<tr>
<td>Headaches</td>
<td>Sometimes</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>Sometimes</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Sources: World Health Organization, Centers for Disease Control and Prevention
Appendix 4: Suggested PPE Guidance

<table>
<thead>
<tr>
<th>Patient type</th>
<th>Change in guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>For symptomatic, unconfirmed in-patients meeting the COVID19 case definition, not having a lung scan</td>
<td>Operators must wear:</td>
</tr>
<tr>
<td></td>
<td>- Regular surgical mask</td>
</tr>
<tr>
<td></td>
<td>- gloves</td>
</tr>
<tr>
<td></td>
<td>- apron</td>
</tr>
<tr>
<td></td>
<td>- strict hand hygiene</td>
</tr>
<tr>
<td>For confirmed cases of COVID-19, and for all in-patient unconfirmed VQ lung scans</td>
<td>Operators must wear full PPE:</td>
</tr>
<tr>
<td></td>
<td>- FFP3 mask or respirator hood</td>
</tr>
<tr>
<td></td>
<td>- disposable eye protection, preferably visor</td>
</tr>
<tr>
<td></td>
<td>- long sleeved gown</td>
</tr>
<tr>
<td></td>
<td>- gloves</td>
</tr>
<tr>
<td></td>
<td>- Scrubs</td>
</tr>
<tr>
<td></td>
<td>- Strict hand hygiene</td>
</tr>
<tr>
<td>For possible and confirmed cases of COVID-19 requiring an aerosol generating procedure</td>
<td>Full PPE ensemble as per previous guidance for confirmed cases: FFP3 respirator, disposable eye protection, preferably visor, long sleeved disposable gown and gloves.</td>
</tr>
</tbody>
</table>
Appendix 5: Proposed Plan for VQs

VQ SPECT PATHWAY

YES

PREGNANT?

NO

**OR MALE PATIENT

LOW SUSPICION OR -VE TEST FOR COVID-19

HIGH SUSPICION OR +VE TEST FOR COVID-19

HIGH SUSPICION OR +VE TEST FOR COVID-19

LOW SUSPICION OR -VE TEST FOR COVID-19

*NORMAL BREATHING NORMAL CXR

RESPIRATORY DISTRESS OR ABNORMAL CXR

ABNORMAL CXR

NORMAL CXR

SPECT VQ

CTPA

SPECT VQ

* RR<20 AND NOT IN RESPIRATORY DISTRESS
PREREQUISITES: ALL PATIENTS ARE REQUIRED TO HAVE HAD A RECENT CXR